Compare FRT & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRT | CORT |
|---|---|---|
| Founded | 1962 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 9.7B |
| IPO Year | 1994 | 2001 |
| Metric | FRT | CORT |
|---|---|---|
| Price | $116.62 | $120.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $112.08 | $96.50 |
| AVG Volume (30 Days) | 815.8K | ★ 1.1M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | ★ 36.84 | N/A |
| EPS | ★ 1.81 | 0.09 |
| Revenue | ★ $1,278,975,000.00 | $761,407,000.00 |
| Revenue This Year | $6.10 | $26.08 |
| Revenue Next Year | $4.64 | $26.98 |
| P/E Ratio | ★ $64.78 | $1,345.00 |
| Revenue Growth | 6.36 | ★ 12.79 |
| 52 Week Low | $90.03 | $28.66 |
| 52 Week High | $128.21 | $122.21 |
| Indicator | FRT | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 33.49 | 70.05 |
| Support Level | $115.78 | $77.73 |
| Resistance Level | $117.22 | $122.21 |
| Average True Range (ATR) | 1.80 | 3.53 |
| MACD | -0.32 | 0.20 |
| Stochastic Oscillator | 9.71 | 84.57 |
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 104 properties, which includes 28.8 million square feet of retail space and 2,700 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.